Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

5.0K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.0K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

975
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
975
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal dynamics control activity of a glial glutamate transporter.

bioRxiv : the preprint server for biology·2026
Same author

CpG island density predicts CBP/p300 dependency across 3D chromatin clusters.

bioRxiv : the preprint server for biology·2026
Same author

Structural insights into cobalamin loading and reactivation of human methionine synthase.

Nature communications·2026
Same author

Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma.

JCI insight·2026
Same author

Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism.

The EMBO journal·2026
Same author

METTL16 promotes taxane resistance in Triple-Negative Breast Cancer through m <sup>6</sup> A-dependent translational upregulation of ABCB1.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Sep 15, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K

Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer.

Pooneh Koochaki1, Biao Qiu2,3, Jesse A Coker4

  • 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.

Biorxiv : the Preprint Server for Biology
|July 17, 2025
PubMed
Summary

Researchers identified a new way to target SLC1A1/EAAT3, a key transporter in renal cell carcinomas (RCCs). A novel inhibitor binds to a unique pocket, blocking transporter function and showing promise for RCC treatment.

Keywords:
EAAT3RCCSLC1A1cellular IC50cryo-EMdrug-resistant mutantsimpedance assaysin silico dockingmedicinal chemistrymetabolic regulationthermal shift assays

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Related Experiment Videos

Last Updated: Sep 15, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.2K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Area of Science:

  • Biochemistry
  • Structural Biology
  • Oncology

Background:

  • Renal Cell Carcinomas (RCCs) exhibit metabolic dependence on the SLC1A1/EAAT3 transporter.
  • Pharmacological targeting of SLC1A1/EAAT3 presents significant challenges.
  • Understanding the structural basis of SLC1A1/EAAT3 inhibition is crucial for therapeutic development.

Purpose of the Study:

  • To determine the cryo-EM structure of human SLC1A1/EAAT3 bound to the inhibitor 3e.
  • To elucidate the binding mechanism and allosteric inhibition of SLC1A1/EAAT3 by bicyclic imidazo[1,2-α]pyridine-3-amine (BIA) derivatives.
  • To guide the development of novel, more potent SLC1A1/EAAT3 inhibitors for RCC treatment.

Main Methods:

  • Cryo-electron microscopy (cryo-EM) to determine the structure of human SLC1A1/EAAT3.
  • Biochemical assays to assess inhibitor binding and transport activity.
  • Site-directed mutagenesis to investigate the role of the allosteric binding pocket.
  • Medicinal chemistry to synthesize novel BIA derivatives.

Main Results:

  • The cryo-EM structure revealed that compound 3e binds to a membrane-embedded allosteric pocket in the apo state of SLC1A1/EAAT3.
  • Inhibition involves blocking substrate and sodium binding, and preventing essential transport movements.
  • Mutations in the allosteric pocket abolished 3e binding and its cytotoxicity in RCC cells.
  • Newly developed BIA derivatives, PBJ1 and PBJ2, demonstrated enhanced cytotoxicity via SLC1A1/EAAT3 inhibition.

Conclusions:

  • Compound 3e effectively inhibits SLC1A1/EAAT3 by binding to a unique allosteric site.
  • The identified binding site and mechanism provide a basis for designing selective SLC1A1/EAAT3 inhibitors.
  • Structure-guided development of BIA derivatives offers a promising therapeutic strategy against RCC by targeting metabolic vulnerabilities.